You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

Aurobindo Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for AUROBINDO, and what generic and branded alternatives to AUROBINDO drugs are available?

AUROBINDO has five hundred and fourteen approved drugs.

There are nineteen tentative approvals on AUROBINDO drugs.

Summary for Aurobindo

US Patents:	0
Tradenames:	388
Ingredients:	361
NDAs:	514
Patent Litigation for Aurobindo:	See patent lawsuits for Aurobindo
PTAB Cases with Aurobindo as petitioner:	See PTAB cases with Aurobindo as petitioner

Drugs and US Patents for Aurobindo

+ Get email alerts for changes to this table

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo	NEVIRAPINE	nevirapine	SUSPENSION;ORAL	077702-001	May 22, 2012	AA	RX	No	Yes		⤷ Subscribe				⤷ Subscribe
Aurobindo Pharma Ltd	CHLORZOXAZONE	chlorzoxazone	TABLET;ORAL	089853-001	May 4, 1988	AA	RX	No	No		⤷ Subscribe				⤷ Subscribe
Aurobindo Pharma Ltd	DIVALPROEX SODIUM	divalproex sodium	TABLET, DELAYED RELEASE;ORAL	090554-002	Apr 21, 2011	AB	RX	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Aurobindo

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aurobindo Pharma Usa	MAXZIDE	hydrochlorothiazide; triamterene	TABLET;ORAL	019129-001	Oct 22, 1984	4,105,783	⤷ Subscribe
Aurobindo Pharma Usa	MAXZIDE-25	hydrochlorothiazide; triamterene	TABLET;ORAL	019129-003	May 13, 1988	4,444,769	⤷ Subscribe
Aurobindo Pharma Usa	MAXZIDE	hydrochlorothiazide; triamterene	TABLET;ORAL	019129-001	Oct 22, 1984	4,444,769	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for AUROBINDO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03
➤ Subscribe	for Injection	200 mcg/vial	➤ Subscribe	2015-05-01
➤ Subscribe	for Injection	100 mcg/vial and 500 mcg/vial	➤ Subscribe	2015-04-14

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.